Company Overview

Update
Founded:
2006
Headquarters:
Boston, MA
Funding:
$10.20M
Categories:
Biotechnology

Prexa Pharmaceuticals develops small molecule monoamine reuptake inhibitors as a treatment for ADHD, depression and Parkinson’s disease.

Description

Update

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease.

Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Current Team (2)

Update

Board Members and Advisors (1)

Update

Funding Rounds (2) - $10.20M

Update

Investors (2)

Update
  • 8bdba4ca5d499ae8edf0829713a936c0

    Advent Venture Partners

    Advent Venture Partners is one of Europe's most successful growth and venture capital..
  • 35c3d686e4de63ee79a626a2a44a9113

    Shire

    Shire PLC is a specialty biopharmaceutical company. They have a global sales and marketing..

Offices/Locations (1)

Update
  • Office

    184 High Street

    Boston, MA 02110

    USA